Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results have?
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results has 592 citations in the OpenAlex counts ScholarIQ stores.
When was Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results published?
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results has 2023 year in the ScholarIQ index.
What is the open-access status of Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results?
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results has hybrid oa status in the ScholarIQ index.
What is the DOI of Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results?
The DOI for Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results is on the source record.
What is the PMID of Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results?
The PMID for Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results is on the source record.
What is the OpenAlex record for Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results?
The OpenAlex for Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results is on the source record.